Dyakov I N, Zyryanov S K
Mechnikov Research Institute for Vaccine and Sera, 5a Malyy Kazennyy pereulok, Moscow, Russian Federation, 105064.
Peoples' Friendship University of Russia, Medical Institute, Medical Faculty, Department of the Common and Clinical Pharmacology, 6 Miklukho-Maklaya St., Moscow, Russian Federation, 1171986.
Vestn Oftalmol. 2017;133(2):125-129. doi: 10.17116/oftalma20171332125-129.
Neovascular age-related macular degeneration (AMD) is the leading cause of vision loss in older patients. An important role in angiogenesis is played by regulatory mechanisms (an increase in the number of proliferating endothelial and stromal cells and morphological alterations in the vascular network) induced by factors from the vascular endothelial growth factor (VEGF) family. Since 2006, the key treatment of neovascular AMD includes agents that inhibit the activity of VEGF. This review covers the effectiveness and safety of the use of anti-VEGF agents in neovascular AMD patients. A comparison is drawn between monoclonal antibody-based therapy and a new drug from the VEGF-Trap group.
新生血管性年龄相关性黄斑变性（AMD）是老年患者视力丧失的主要原因。血管内皮生长因子（VEGF）家族的因子所诱导的调节机制（增殖的内皮细胞和基质细胞数量增加以及血管网络的形态改变）在血管生成中起重要作用。自2006年以来，新生血管性AMD的关键治疗方法包括抑制VEGF活性的药物。本综述涵盖了抗VEGF药物在新生血管性AMD患者中的有效性和安全性。文中对基于单克隆抗体的疗法与VEGF-Trap组的一种新药进行了比较。
